Diseases / Erectile Dysfunction
Erectile Dysfunction
DiseaseErectile dysfunction is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It is a multifactorial condition with organic, psychogenic, and mixed etiologies, and is strongly associated with cardiometabolic comorbidities and age. It can substantially affect quality of life and mental health.
- Trials
- 660
- Recruiting
- 54
- Completed
- 374
- With results
- 69
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | 1 | — | 1 | — | — | 1 | 3 |
| Phase 1 | 2 | 5 | — | — | 48 | — | 2 | — | 5 | 62 |
| Phase 1/2 | 2 | — | — | — | 5 | — | 2 | — | 6 | 15 |
| Phase 2 | 4 | 5 | — | 2 | 36 | 4 | 1 | — | 8 | 60 |
| Phase 2/3 | 3 | — | — | — | 4 | — | — | — | 3 | 10 |
| Phase 3 | 1 | 2 | — | 3 | 74 | 4 | 1 | — | 14 | 99 |
| Phase 4 | 3 | 2 | — | — | 80 | 1 | 3 | — | 14 | 103 |
| Not applicable | 28 | 11 | 2 | 5 | 71 | 8 | 12 | — | 56 | 193 |
| Unknown | 11 | 6 | 4 | 5 | 56 | 7 | 1 | 1 | 24 | 115 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Erectile Dysfunction | 3 | 62 | 15 | 60 | 10 | 99 | 103 | 193 | 115 | 660 |
| Prostatic Neoplasms | — | 1 | 2 | 8 | 1 | 6 | 2 | 21 | 10 | 51 |
| Sexual Dysfunction, Physiological | — | 1 | 2 | 3 | 2 | 9 | 2 | 8 | 14 | 41 |
| Urinary Incontinence | — | — | 1 | 1 | — | 1 | — | 14 | 4 | 21 |
| Prostatic Hyperplasia | — | 4 | — | 2 | — | 5 | 1 | 4 | 4 | 20 |
| Premature Ejaculation | — | — | — | — | — | 6 | 2 | 4 | 6 | 18 |
| Diabetes Mellitus | — | 1 | — | — | — | 4 | 2 | 4 | 4 | 15 |
| Hypogonadism | 1 | — | — | 4 | — | 2 | 2 | 2 | 2 | 13 |
| Sexual Dysfunctions, Psychological | — | — | — | 2 | — | 3 | — | 2 | 6 | 13 |
| Lower Urinary Tract Symptoms | — | — | — | 1 | 1 | 1 | 1 | 4 | 3 | 11 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Bayer | 51 | 22 |
| 2 | Eli Lilly and Company | 28 | 13 |
| 3 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 27 | 0 |
| 4 | Cairo University | 16 | 1 |
| 5 | VIVUS LLC | 15 | 4 |
| 6 | Rambam Health Care Campus | 14 | 9 |
| 7 | Vigonvita Life Sciences | 10 | 2 |
| 8 | Institute for the Study of Urological Diseases, Greece | 7 | 1 |
| 9 | Pfizer | 7 | 1 |
| 10 | Mayo Clinic | 6 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Tadalafil | 80 |
| 2 | Sildenafil Citrate | 76 |
| 3 | Vardenafil Dihydrochloride | 58 |
| 4 | avanafil | 17 |
| 5 | udenafil | 12 |
| 6 | Extracorporeal Shockwave Therapy | 10 |
| 7 | dapoxetine | 7 |
| 8 | 2-(5-(4-(2-hydroxyethyl)piperazin-1-ylsulfonyl)-2-n-propoxyphenyl)-5-ethyl-7-n-propyl-3,5-dihydro-4H-pyrrolo(3,2-d)pyrimidin-4-one dihydrochloride | 6 |
| 9 | Exercise | 6 |
| 10 | Surveys and Questionnaires | 6 |
Evidence
- Results reported
- 18.4%69 of 374 completed
- Published
- 9.1%34 of 374 completed
- Primary endpoint met
- 82.1%55 of 67 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 76
- Median duration
- 15months
- Countries
- 68
- Study sites
- 2031
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 74
- Phase 1
- 24
- Phase 1/2
- 30
- Phase 2
- 72
- Phase 2/3
- 83
- Phase 3
- 280
- Phase 4
- 160
- Not applicable
- 50
- Unknown
- 130
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 37 |
| 2 | San Diego | United States | 30 |
| 3 | San Antonio | United States | 24 |
| 4 | Houston | United States | 20 |
| 5 | Huntsville | United States | 19 |
| 6 | Haifa | Israel | 18 |
| 7 | Seoul | South Korea | 18 |
| 8 | Aventura | United States | 17 |
| 9 | Cairo | Egypt | 17 |
| 10 | Phoenix | United States | 17 |
Terminations
- Terminated
- 25
- Withdrawn
- 22
- Suspended
- 1
- Stopped for recruitment
- 1.8%12 of 660 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06469775 Withdrawn | Withdrawn | Institution unable to purchase machine to start study. | 2031-09-01 |
| NCT06098755 Withdrawn | Withdrawn | No Participants Enrolled | 2028-12-31 |
| NCT06152146 Withdrawn | Withdrawn | Study submission was discarded with the IRB and no longer moving forward | 2026-06-01 |
| NCT04002661 Terminated | Terminated | The study's inclusion and exclusion criteria are tight and could not enroll any patients | 2026-01-23 |
| NCT06347575 Withdrawn | Withdrawn | The company that supplies the Medical Device has withdrawn. | 2025-11-30 |
| NCT05366842 Terminated | Terminated | The sponsor was unable to produce and provide the study material (stravix) | 2025-04-25 |
| NCT05484167 Withdrawn | Withdrawn | They study lost funding and decided to close the study down. | 2025-04-01 |
| NCT05646602 Withdrawn | Withdrawn | No participants enrolled | 2024-12-31 |
| NCT05929300 Withdrawn | Withdrawn | Lack of recruitment | 2024-09-04 |
| NCT05081232 Withdrawn | Withdrawn | Study will not be conducted | 2024-08-31 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Erectile Dysfunction trials on ClinicalTrials.gov →